BR102018074043A2 - composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias - Google Patents

composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias Download PDF

Info

Publication number
BR102018074043A2
BR102018074043A2 BR102018074043A BR102018074043A BR102018074043A2 BR 102018074043 A2 BR102018074043 A2 BR 102018074043A2 BR 102018074043 A BR102018074043 A BR 102018074043A BR 102018074043 A BR102018074043 A BR 102018074043A BR 102018074043 A2 BR102018074043 A2 BR 102018074043A2
Authority
BR
Brazil
Prior art keywords
pathways
modulating
compound
composition
rlr
Prior art date
Application number
BR102018074043A
Other languages
English (en)
Inventor
Marisa Chudzinski Tavassi Ana
Deocesano Pereira Carlos
Linchtenstein Flávio
Gabriel De Souza Jean
Luciano Pereira Morais Katia
Barbugiani Goldfeder Maurício
Chammas Roger
Original Assignee
Inst Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Butantan filed Critical Inst Butantan
Priority to BR102018074043A priority Critical patent/BR102018074043A2/pt
Priority to US17/296,090 priority patent/US20220370577A1/en
Priority to EP19887425.7A priority patent/EP3939995A4/en
Priority to PCT/BR2019/050502 priority patent/WO2020102875A1/pt
Publication of BR102018074043A2 publication Critical patent/BR102018074043A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43527—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from ticks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção é nos campos das ciências farmacêuticas, imunologia e métodos de tratamento do câncer. mais especificamente, refere-se a um composto para modular uma ou mais vias imunes inatas selecionadas de rlr, tlr, oas e/ou oncostatina m. o uso do referido composto na preparação de medicamentos; uma composição e um método para modular as referidas vias; e uma composição farmacêutica compreendendo o referido composto também são descritos.
BR102018074043A 2018-11-22 2018-11-22 composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias BR102018074043A2 (pt)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR102018074043A BR102018074043A2 (pt) 2018-11-22 2018-11-22 composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias
US17/296,090 US20220370577A1 (en) 2018-11-22 2019-11-22 Compound for modulating rlr, tlr, oas and/or oncostatin m pathways, use thereof for preparing a medicine, composition, method for modulating said pathways and method of treatment
EP19887425.7A EP3939995A4 (en) 2018-11-22 2019-11-22 COMPOUND FOR MODULATION OF RLR, TLR, OAS AND/OR ONCOSTATIN-M SIGNALING PATHWAYS, USE THEREOF IN THE MANUFACTURE OF A MEDICINAL PRODUCT, COMPOSITION, METHODS OF MODULATION OF SAID SIGNALING PATHWAYS AND METHODS OF TREATMENT
PCT/BR2019/050502 WO2020102875A1 (pt) 2018-11-22 2019-11-22 Composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição, método para modulação das ditas vias e método de tratamento

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102018074043A BR102018074043A2 (pt) 2018-11-22 2018-11-22 composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias

Publications (1)

Publication Number Publication Date
BR102018074043A2 true BR102018074043A2 (pt) 2020-06-02

Family

ID=70773031

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102018074043A BR102018074043A2 (pt) 2018-11-22 2018-11-22 composto para a modulação de vias de rlr, tlr, oas e/ou oncostatina m, uso do mesmo para a preparação de um medicamento, composição e método para modulação das ditas vias

Country Status (4)

Country Link
US (1) US20220370577A1 (pt)
EP (1) EP3939995A4 (pt)
BR (1) BR102018074043A2 (pt)
WO (1) WO2020102875A1 (pt)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0406057B1 (pt) * 2004-09-15 2021-10-26 União Química Farmacêutica Nacional S/A Sequência nucleotídica de um inibidor de proteases do tipo kunitz obtida a partir de uma biblioteca de cdna de glândulas salivarares de carrapatos amblyomma cajennese uso da proteína recombinante
KR100794071B1 (ko) 2006-12-05 2008-01-10 한국원자력연구원 핵연료 소결체의 제조 방법
AU2008226358A1 (en) * 2007-03-14 2008-09-18 Ana Marisa Chudzinski-Tavassi Kunitz-type recombinant inhibitor

Also Published As

Publication number Publication date
US20220370577A1 (en) 2022-11-24
EP3939995A4 (en) 2022-11-30
WO2020102875A1 (pt) 2020-05-28
EP3939995A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA201792304A1 (ru) Комбинированная терапия для лечения рака
BR112019007576A2 (pt) compostos de bifenil sulfonamida para o tratamento de doenças ou transtornos renais
BR112015025025A2 (pt) composições terapêuticas e usos das mesmas
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
BR112016006994A2 (pt) inibidores de erk e métodos de uso
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
BR112016027435A2 (pt) formulação inovadora de meloxicam
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CL2016000148A1 (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
BR112017002878A2 (pt) distribuição coordenada de tratamento de copd

Legal Events

Date Code Title Description
B11K Dismissal acc. art. 17, par 2 of ipl - pending earlier application (priority claim) definitively shelved

Free format text: PRIORIDADE INTERNA DO BR102019024715-0 DE 22/11/2019.

B03F Publication of an application: publication of application definitely dismissed [chapter 3.6 patent gazette]